Drug Profile
AV 203 companion diagnostic - Amoy Diagnostics/CANbridge Pharmaceuticals
Alternative Names: CAN 017 companion diagnostic - Amoy Diagnostics/CANbridge PharmaceuticalsLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Amoy Diagnostics
- Developer Amoy Diagnostics; CANbridge Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Oesophageal cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Oesophageal-cancer(Diagnosis) in China
- 21 Dec 2017 CANbridge enter into a partnership with Amoy Diagnostics to develop AV 203 (CAN 017) biomarker companion diagnostic for Oesophageal cancer (Diagnosis)
- 21 Dec 2017 Early research in Oesophageal cancer (Diagnosis) in China (unspecified route)